Medical Equipment Companies By Enterprise Value

Current Valuation
Current ValuationEfficiencyMarket RiskExp Return
1EW Edwards Lifesciences Corp
38.42 B
(0.04)
 1.60 
(0.06)
2DXCM DexCom Inc
27.15 B
(0.07)
 2.43 
(0.16)
3MMSI Merit Medical Systems
6.49 B
 0.08 
 1.56 
 0.12 
4NVST Envista Holdings Corp
3.4 B
(0.03)
 2.41 
(0.07)
5WRBY Warby Parker
2.23 B
(0.10)
 3.55 
(0.36)
6EMBC Embecta Corp
2.09 B
(0.26)
 2.97 
(0.77)
7NVCR Novocure
1.8 B
(0.24)
 2.92 
(0.71)
8ESTA Establishment Labs Holdings
1.31 B
 0.00 
 5.80 
 0.00 
9MDXG MiMedx Group
1.03 B
(0.19)
 1.84 
(0.36)
10BBNX Beta Bionics, Common
891.53 M
(0.34)
 4.68 
(1.59)
11CBLL CeriBell,
776.09 M
(0.11)
 3.64 
(0.40)
12NPCE Neuropace
406.42 M
 0.07 
 3.86 
 0.29 
13AVR Anteris Technologies Global
279.73 M
(0.07)
 4.77 
(0.35)
14OM Outset Medical
265.83 M
(0.04)
 8.00 
(0.31)
15NNOX Nano X Imaging
257.17 M
(0.07)
 5.62 
(0.37)
16BDMD Baird Medical Investment
248.19 M
 0.13 
 81.02 
 10.59 
17NYXH Nyxoah
232.33 M
 0.02 
 4.43 
 0.10 
18ELMD Electromed
186.05 M
(0.10)
 3.35 
(0.34)
19NVRO Nevro Corp
182.72 M
 0.19 
 4.37 
 0.83 
20DRTS Alpha Tau Medical
140.15 M
(0.06)
 4.10 
(0.23)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents. Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.